Skip to content
Evigrade
CriticalAntiretroviral, HIV protease inhibitor×Class Ia antiarrhythmic (sodium channel blocker with intermediate kinetics)

Updated · Methodology

Mechanism

The liver eliminates most quinidine through CYP3A4 (quinidine label, US Food and Drug Administration, FDA), and atazanavir inhibits this enzyme, so quinidine levels can rise (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA). Quinidine has a narrow therapeutic margin, and the atazanavir SmPC contraindicates it precisely because of the potential CYP3A inhibition (EMA). Ritonavir inhibits this enzyme more strongly than atazanavir itself, and cobicistat is also a potent CYP3A inhibitor (atazanavir and atazanavir/cobicistat SmPCs, EMA). Quinidine prolongs the QT interval in a dose-related way, and this may lead to polymorphic ventricular tachycardia, including torsade de pointes (FDA quinidine label). The documents give no figures for this pair.

Symptoms

The danger of this combination is serious or life-threatening reactions such as cardiac arrhythmias (atazanavir label, US Food and Drug Administration, FDA). QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. Besides torsade de pointes, quinidine can cause frequent extrasystoles, ventricular tachycardia, ventricular flutter and ventricular fibrillation. The risk of torsade de pointes rises with a slow heart rate, low potassium, magnesium or calcium and high quinidine levels, although it can also occur without these factors (FDA quinidine label). In some people atazanavir prolongs the PR interval: atrioventricular conduction changes are usually asymptomatic and generally limited to first-degree block, but second-degree block has also been reported (atazanavir FDA label).

Management

The combination is contraindicated. The European atazanavir summary of product characteristics (SmPC) lists quinidine among its contraindications whether or not a booster is used (atazanavir SmPC, European Medicines Agency, EMA), and the atazanavir/cobicistat SmPC also contraindicates it (EMA). The US atazanavir label contraindicates quinidine in regimens with ritonavir. Without ritonavir, the combination has not been studied, and for that regimen the label advises caution and monitoring of quinidine concentrations (atazanavir label, US Food and Drug Administration, FDA). The European SmPC is stricter. With ritonavir, the ritonavir SmPC also contraindicates quinidine (ritonavir SmPC, EMA). Quinidine is not in the Spanish medicines register CIMA, which lists only hydroquinidine, a different substance. If the drugs have nevertheless been taken together and haemodynamically unstable polymorphic ventricular tachycardia, including torsade de pointes, develops, stop quinidine and perform immediate cardioversion or overdrive pacing. Look for low potassium, magnesium and calcium and, if possible, correct them promptly (FDA quinidine label, overdosage section).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Atazanavir

Other interactions with Quinidine